Skip to main content

Table 2 Body weight, heart weight, heart-to-body weight ratio, heart weight-to-tibia length ratio and left-ventricular wall thickness assessed by echocardiography

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

 

ZL

(n = 7–10)

ZDF

(n = 7–8)

ZDF + Zn(ASA)2

(n = 5–6)

ZL + Zn(ASA)2

(n = 8–10)

Weights

 Body weight (g)

419 ± 9

376 ± 18

394 ± 27

416 ± 6

 Heart weight (g)

1.36 ± 0.03

1.22 ± 0.04

1.35 ± 0.14

1.32 ± 0.03

 Heart-to-body weight (g/kg)

3.26 ± 0.05

3.26 ± 0.11

3.39 ± 0.10

3.19 ± 0.07

 Heart weight-to-tibia length (g/cm)

0.32± 0.01

0.30 ± 0.01

0.33 ± 0.03

0.30 ± 0.01

Left-ventricular wall thickness

 LVPW, d (mm)

2.49 ± 0.31

2.95 ± 0.42

1.95 ± 0.17

1.94 ± 0.20

 LVPW, s (mm)

3.20 ± 0.27

4.24 ± 0.40

3.16 ± 0.19

2.69 ± 0.25

  1. Values are mean ± SEM. ZL indicates Zucker lean, ZDF Zucker diabetic fatty acid, Zn(ASA) 2 zinc complex of acetylsalicylic acid, LVPW, d, thickness of the left ventricular posterior wall in diastole, LVPW, s thickness of the left ventricular posterior wall in systole, n number of animals analysed